Russell Szmulewitz

Q&A: A New Kind of Cancer Vaccine

May 19, 2010

At the end of April, an FDA approval marked the end of a long regulatory road for an interesting drug with an even more interesting history: Provenge. Though it’s usually described as a vaccine for metastatic prostate cancer, that terminology [Read more]